Clinical trials: Urinary
Non-muscle-invasive Bladder Cancer
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.
- Trial name
- NCT05710848
- Testing
- STM-416
- Where
- 20 sites in United States
- Volunteers
- 75 people
- Sponsor
- SURGE Therapeutics
Cystocele
Nerve Access Tool Study
The purpose of this study is to assess the ability of the nerve access tool to facilitate nerve stimulation lead placement.
- Trial name
- NCT00942474
- Testing
- Facilitate nerve stimulation lead placement with the nerve access tool
- Sponsor
- MedtronicNeuro
Nocturia
A Study of Minirin Melt in 24 Months Treatment in Patients With Nocturia
A Confirmation of the Safety Profile for Minirin Melt in Clinical Practice
- Trial name
- NCT01552395
- Where
- 68 sites in Czechia
- Volunteers
- 4,136 people
- Sponsor
- Ferring Pharmaceuticals
Urinary Incontinence, Urge
CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology
This is a prospective, randomized, controlled, multi-center, study in which 150 evaluable subjects will be randomized 1:1 to receive either a Protect CAN-Stim or SNS InterStim® system.
- Trial name
- PROTECT (NCT02577302)
- Testing
- CAN-Stim - Protect CAN-Stim System, SNS - InterStim® System
- Where
- 15 sites in United States
- Volunteers
- 200 people
- Sponsor
- Uro Medical Corporation
Benign Prostatic Hyperplasia
Interest of a Systematic Assessment of the Treatment of LUTS in the Management of BPH
The high level of unsatisfactory outcome observed in patients treated for LUTS associated with BPH with respect to the different existing therapeutic options strongly emphasizes the need for treatment optimisation in daily…
- Trial name
- UROEVAL (NCT03179670)
- Where
- France
- Volunteers
- 625 people
- Sponsor
- RECORDATI GROUP
Overactive Bladder, Urinary Urgency Incontinence
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.
- Conditions
- Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer
- Trial name
- NCT06511141
- Testing
- Axonics SNM System
- Where
- 23 sites in United States
- Volunteers
- 150 people
- Sponsor
- Axonics, Inc.
Overactive Bladder
Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder
Tolterodine is approved for use in the treatment of overactive bladder (OAB). The study is designed to a investigate whether pregabalin may have efficacy in OAB and whether the efficacy is altered when it is combined with…
- Trial name
- NCT00746681
- Testing
- Tolterodine & Pregabalin, Tolterodine, Pregabalin
- Where
- 23 sites in Czechia, Lithuania and 4 more
- Volunteers
- 188 people
- Sponsor
- Pfizer
Urinary Incontinence
Collection of Real-life Measurement Data for TENA SmartCare Change Indicator in Subjects With Urinary Incontinence
This study is an explorative, open, single-arm clinical investigation to collect real-life measurement data in order to assess the mathematical algorithms involved in TENA SmartCare Change Indicator.
- Trial name
- NCT04071301
- Testing
- TENA SmartCare Change Indicator
- Where
- Sweden
- Volunteers
- 15 people
- Sponsor
- Essity Hygiene and Health AB
Lithotripsy, Laser
TELAXMAN - Laser Lithotripsy With Automatic Real-time Stone Recognition
Urolithiasis is an extremely common disease affecting about 12% of the world population with increasing tendency. Urinary stones are sediments that form in the kidney from crystals, such as calcium oxalate.
- Trial name
- NCT05500534
- Testing
- Laser lithotripsy with stone recognition, Laser lithortripsy
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- LISA Laser Products GmbH
Stress Urinary Incontinence
Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
The objective of this single arm, post market, clinical study is to evaluate the performance of Gynecare TVT ABBREVO® Continence System in women undergoing Mid-urethral sling surgery for Stress Urinary Incontinence (SUI).
- Trial name
- NCT04829357
- Testing
- Intervention
- Where
- 4 sites in United States, Italy and 1 more
- Volunteers
- 195 people
- Sponsor
- Ethicon, Inc.
NMIBC
ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer
This is an open-label, randomized, phase 3 study of intravesical BCG plus ANKTIVA (experimental arm) versus BCG alone (control arm) in participants who have histologically confirmed, BCG-naïve/BCG-exposed high-grade Ta/T1…
- Trial name
- NCT07551544
- Testing
- BCG (50 mg) plus ANKTIVA (400 µg), BCG (50 mg)
- Sponsor
- ImmunityBio, Inc.
Non-Muscle-Invasive Bladder Cancer (NMIBC)
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC
This is an open-label, multicenter phase 1 study to evaluate the safety, efficacy, and pharmacokinetics (PK) characteristics of SIM0237 alone or in combination with bacillus Calmette-Guerin (BCG) in participants with…
- Trial name
- NCT06186414
- Testing
- SIM0237, SIM0237 and BCG
- Where
- 14 sites in China
- Volunteers
- 152 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Urinary Bladder Neoplasms, Urologic Neoplasms
A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer
The main purpose of this study is to see how well vepugratinib works in adults with low grade, intermediate risk, non-muscle invasive bladder cancer (LG IR NMIBC) or low-grade upper tract urothelial carcinoma (LG UTUC).
- Conditions
- Urinary Bladder Neoplasms, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3
- Trial name
- FORAY (NCT07827612)
- Testing
- Vepugratinib
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Eli Lilly and Company
Prostatism, Erectile Dysfunction
Study of Dr. Pyke's Supplement for Stream (S4S) in Men With Prostatism and ED
This is the first clinical trial of Dr. Pyke's Supplement for Stream (S4S), a proprietary combination of Panax ginseng extract, L-citrulline, beta-sitosterol and vitamin D3, to investigate its effects on prostatism and erections…
- Trial name
- S4S4BPH/ED (NCT03681392)
- Testing
- Dr. Pyke's Supplement for Stream (S4S)
- Sponsor
- Robert E. Pyke
Bladder Cancer, Kidney Cancer
Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Bladder Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00016237
- Testing
- tucotuzumab celmoleukin
- Where
- 2 sites in United States
- Sponsor
- EMD Serono
Urinary Incontinence, Stress, Intrinsic Sphincter Deficiency
AMS AdVance and AdVance XP Male Sling Systems for the Treatment of Stress Urinary Incontinence Following Prostatectomy: Evaluation of Safety, Efficacy, and Quality of Life Through Retrospective Chart Review and Prospective Follow-up
A single-center retrospective chart review of AdVance and AdVance XP subject data, combined with prospective follow-up of the same subjects to confirm continence, adverse event, and quality of life status.
- Trial name
- NCT01725984
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- American Medical Systems
Urinary Tract Infection
Temocillin Use in Complicated Urinary Tract Infections Due to Extended Spectrum Beta-Lactamases (ESBL)/AmpC Enterobacteriaceae
This study is aimed at demonstrating the efficacy of temocillin in the treatment of complicated Urinary Tract Infection (UTI) due to confirmed Extended Spectrum Beta-Lactamases (ESBL) producing or AmpC hyperproducing…
- Trial name
- TEA (NCT01543347)
- Testing
- Temocillin
- Where
- United Kingdom
- Sponsor
- Belpharma s.a.
Urinary Incontinence, Urge
A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence
The purpose of this study is to determine the safety of three doses of oxybutynin for the treatment of urge urinary incontinence.
- Trial name
- FP1097-002 (NCT00749632)
- Testing
- oxybutynin
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- FemmePharma Global Healthcare, Inc.
Overactive Bladder
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.
To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder
- Trial name
- NCT00611026
- Testing
- Tolterodine ER, Fesoterodine
- Where
- 227 sites in United States, Brazil and 23 more
- Volunteers
- 2,417 people
- Sponsor
- Pfizer